Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oxaliplatin + 5-fluorouracil + cetuximab with radiotherapy in inoperable locally advanced oesophageal or cardia cancer
2008-006802-40Phase 2Terminated
- Sponsor
- Karolinska University Hospital
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in esophageal cancer and gastroesophageal junction adenocarcinoma, sponsored by Karolinska University Hospital. Primary endpoint: Local tumour control at 1 year. Started Oct 2010; status: terminated.
02
Drugs
cetuximab
03
Conditions
esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2008-006802-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006802-40.